Clinical Trials on Metabolic Dysfunction-associated Steatohepatitis (MASH) in Chile

Total 9 results

Inventiva Pharma

Recruiting

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)

NASH - Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Austria, Belgium, France, Germany, Israel, Portugal, Spain, United Kingdom, Canada, Italy, China, Brazil, Netherlands, Hungary, Bulgaria, Chile, Czechia, Mexico, Poland, Puerto Rico, South Africa, Uk...
Genfit

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

Nonalcoholic Steatohepatitis (NASH) With Fibrosis

United States, Belgium, Germany, France, Canada, Netherlands, Italy, Switzerland, Finland, Puerto Rico, United Kingdom, Denmark, Spain, Australia, Czechia, Sweden, Romania, Argentina, Portugal, Turkey, Mexico, Colombia, South Africa, ... and more
Novartis Pharmaceuticals

Terminated

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (ELIVATE)

Non Alcoholic Steatohepatitis (NASH)

United States, South Africa, Spain, Germany, Italy, Taiwan, Canada, Korea, Republic of, Singapore, Bulgaria, Estonia, Mexico, Japan, Denmark, United Kingdom, Colombia, Brazil, Belgium, Russian Federation, Puerto Rico, Chile, Argen... and more
Galectin Therapeutics Inc.

Active, not recruiting

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NAVIGATE)

Cirrhosis | NASH - Nonalcoholic Steatohepatitis | Prevention of Esophageal Varices

United States, France, Spain, Australia, Canada, Israel, Puerto Rico, Belgium, Argentina, Chile, Germany, Korea, Republic of, Mexico, Poland, United Kingdom
Cristian Alvarez

Completed

Inter-individual Physiological Response to a Training and Detraining Period in Cardiometabolic Risk Factors Subjects (VASCU-HEALTH)

Endothelial Dysfunction | Arterial Hypertension | Physical Inactivity | Vascular Disease, Peripheral

Chile
Instituto para el Desarrollo Biotecnológico y la...
Corporación de Fomento de la Producción, Chile

Recruiting

Cell Therapy for Diabetic Foot Ulcer

Wound Heal | Diabetic Foot Ulcer Associated With Type II Diabetes Mellitus

Chile
Galmed Research and Development, Ltd.
Medical University of Graz; Tel-Aviv Sourasky Medical Center; Fondazione IRCCS... and other collaborators

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (Aramchol_005)

Liver Diseases | Fatty Liver | Non-Alcoholic Steatohepatitis | Liver Fibroses

United States, Chile, Israel, Italy, France, Germany, Mexico, Georgia, Lithuania, Hong Kong, Romania
Sanofi

Terminated

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Fatty Liver

United States, France, Brazil, Poland, Romania, Germany, Portugal, Spain, Switzerland, Malaysia, Philippines, Taiwan, Belgium, Mexico, Argentina, Croatia, Hungary, Italy, Colombia, Chile, United Kingdom, Puerto Rico, Australia, China
Sanofi

Terminated

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

Fatty Liver

United States, France, Brazil, Poland, Romania, Germany, Portugal, Spain, Switzerland, Malaysia, Philippines, Taiwan, Belgium, Mexico, Argentina, Croatia, Hungary, Italy, Colombia, Chile, United Kingdom, Puerto Rico, Australia, China

Clinical Trials on Metabolic Dysfunction-associated Steatohepatitis (MASH) in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations